Publication: Antiseizure medication for brain metastasis-related epilepsy: Findings of optimal choice from a retrospective cohort
Authors
Sánchez-Villalobos, José Manuel ; Aledo-Serrano, Ángel ; Serna-Berna, Alfredo ; Salinas-Ramos, Juan ; Martínez Alonso, Emma ; Pérez-Vicente, José Antonio ; Alcaraz Baños, Miguel
item.page.secondaryauthor
Facultad de Medicina
item.page.director
Publisher
Elsevier
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1016/J.EPLEPSYRES.2021.106812
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Objective: To analyze the prevalence of antiseizure medication (ASM) in patients with brain metastasis-related epilepsy (BMRE) treated with radiosurgery and the relationship between ASM and psychiatric comorbidity. Material and methods: This is a cross-sectional observational design study with retrospective review of medical records of all patients with brain metastases treated with volumetric modulated arc therapy radiosurgery (VMAT-RS) between 2012 and 2018 in a tertiary oncology center. We included those patients with BMRE, analyzing the clinical and demographic data, with special attention to psychiatric comorbidities and the use of ASM. Results: Of the 121 patients with brain metastases included for treatment with VMAT-RS, a total of 38 presented BMRE. The most widely used ASM as first-line treatment was levetiracetam (89%). Only 8% of the patients received sodium channel blockers. The most common psychiatric comorbidity was depression (42.1%). Conclusions: Levetiracetam is the most widely used ASM in patients with BMRE treated with VMAT-RS. Nevertheless, common psychiatric comorbidities in this population might change the decision-making of ASM choice.
publication.page.subject
Citation
Epilepsy Research 178 (2021) 106812
item.page.embargo
Collections
Ir a Estadísticas
Sin licencia Creative Commons.